The design and discovery of novel amide CCR5 antagonists

被引:18
作者
Pryde, David C. [1 ]
Corless, Martin [1 ]
Fenwick, David R. [1 ]
Mason, Helen J. [1 ]
Stammen, Blanda C. [1 ]
Stephenson, Peter T. [1 ]
Ellis, David [1 ]
Bachelor, David [1 ]
Gordon, David [1 ]
Barber, Christopher G. [1 ]
Wood, Anthony [1 ]
Middleton, Donald S. [1 ]
Blakemore, David C. [1 ]
Parsons, Gemma C. [1 ]
Eastwood, Rachel [1 ]
Platts, Michelle Y. [1 ]
Statham, Keith [1 ]
Paradowski, Kerry A. [1 ]
Burt, Catherine [1 ]
Klute, Wolfgang [1 ]
机构
[1] Pfizer Global Res & Dev, Dept Chem, Sandwich CT13 9NJ, Kent, England
关键词
CCR5; Antagonist; Chemokine; HIV; AIDS; Antiviral; SMALL-MOLECULE INHIBITOR; CHEMOKINE RECEPTOR CCR5; HIV-1; INFECTION; BIOLOGICAL EVALUATION; BINDING POCKET; POTENT; SCH-351125; ENTRY; UK-427,857; MARAVIROC;
D O I
10.1016/j.bmcl.2009.01.012
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1084 / 1088
页数:5
相关论文
共 21 条
[1]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[2]  
Barber Chris G, 2004, Curr Opin Investig Drugs, V5, P851
[3]   Nonpeptidic ligands for peptide-activated g protein-coupled receptors [J].
Blakeney, Jade S. ;
Reid, Robert C. ;
Le, Giang T. ;
Fairlie, David P. .
CHEMICAL REVIEWS, 2007, 107 (07) :2960-3041
[4]   Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry [J].
Bradley, J ;
Gill, J ;
Bertelli, F ;
Letafat, S ;
Corbau, R ;
Hayter, P ;
Harrison, P ;
Tee, A ;
Keighley, W ;
Perros, M ;
Ciaramella, G ;
Sewing, A ;
Williams, C .
JOURNAL OF BIOMOLECULAR SCREENING, 2004, 9 (06) :516-524
[5]   Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: A molecular modeling-guided mutagenesis study the binding pocket [J].
Castonguay, LA ;
Weng, YM ;
Adolfsen, W ;
Di Salvo, J ;
Kilburn, R ;
Caldwell, CG ;
Daugherty, BL ;
Finke, PE ;
Hale, JJ ;
Lynch, CL ;
Mills, SG ;
MacCoss, M ;
Springer, MS ;
DeMartino, JA .
BIOCHEMISTRY, 2003, 42 (06) :1544-1550
[6]   IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].
COCCHI, F ;
DEVICO, AL ;
GARZINODEMO, A ;
ARYA, SK ;
GALLO, RC ;
LUSSO, P .
SCIENCE, 1995, 270 (5243) :1811-1815
[7]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732
[8]   CCR5 inhibitors in HIV-1 therapy [J].
Dorr, Patrick ;
Perros, Manos .
EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) :1345-1361
[9]  
DORR PK, 2008, M MOL PHARM, V73, P789
[10]   A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5 [J].
Dragic, T ;
Trkola, A ;
Thompson, DAD ;
Cormier, EG ;
Kajumo, FA ;
Maxwell, E ;
Lin, SW ;
Ying, WW ;
Smith, SO ;
Sakmar, TP ;
Moore, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5639-5644